Literature DB >> 28196379

Pulmonary Embolism and Atrial Fibrillation: Two Sides of the Same Coin? A Systematic Review.

Behnood Bikdeli1,2,3, Maen D Abou Ziki4, Gregory Y H Lip5,6.   

Abstract

Pulmonary embolism (PE) is a common, potentially fatal thrombotic disease. Atrial fibrillation (AF), the most common arrhythmia, may also lead to thromboembolic complications. Although initially appearing as distinct entities, PE and AF may coexist. The direction and extent of this association has not been well characterized. We performed a search of PubMed, Scopus, and the Cochrane Database of Systematic Reviews for publications that reported coexisting AF in patients with PE, or vice versa, to provide a systematic overview of pathophysiological and epidemiological aspects of this association (last search: October 13, 2016). We screened 650 articles following the PubMed search, and 697 through Scopus. PE and AF share many common risk factors, including old age, obesity, heart failure, and inflammatory states. In addition, PE may lead to AF through right-sided pressure overload or inflammatory cytokines. AF, in turn, might lead to right atrial appendage clot formation and thereby PE. Epidemiological studies indicate that AF can be seen as a presenting sign, during the early phase, or later in the course of recovery from PE. Patients with AF are also at increased risk of developing PE, a risk that correlates with the CHA2DS2-VASc score. For the choice of antithrombotic therapy, PE-related factors (provoked or unproved, active cancer, and prior recurrence) and AF-related factors (CHA2DS2-VASc score), risk of bleeding, and patient preferences should be considered. In conclusion, PE and AF may coexist, with an understudied bidirectional association. Prognostication and choice of antithrombotic therapy in patients with both PE and AF might be different compared with those who present with only one of the two and warrants further investigation. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28196379     DOI: 10.1055/s-0036-1598005

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  10 in total

1.  Atrial fibrillation and venous thromboembolism: evidence of bidirectionality in the Atherosclerosis Risk in Communities Study.

Authors:  P L Lutsey; F L Norby; A Alonso; M Cushman; L Y Chen; E D Michos; A R Folsom
Journal:  J Thromb Haemost       Date:  2018-03-13       Impact factor: 5.824

2.  Atrial fibrillation is related to lower incidence of deep venous thrombosis in patients with pulmonary embolism.

Authors:  Khalid Bin Waleed; Xumin Guan; Xintao Li; Yiheng Yang; Zhao Wang; Xiaomeng Yin; Zhengyan Wang; Jianghai Liu; Lianjun Gao; Dong Chang; Xianjie Xiao; Rongfeng Zhang; Gary Tse; Yunlong Xia
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

3.  Quantifying Risk Factors for Atrial Fibrillation: Retrospective Review of a Large Electronic Patient Database.

Authors:  Jaclyn Rivington; Patrick Twohig
Journal:  J Atr Fibrillation       Date:  2020-10-31

4.  Ischemic stroke risk estimation in patients without oral anticoagulation: an observational cohort study based on secondary data from Germany.

Authors:  Felix S Wicke; Martin A Schaller; Kateryna Karymova; Martin Beyer; Beate S Müller
Journal:  BMC Cardiovasc Disord       Date:  2019-04-23       Impact factor: 2.298

5.  Type 2 Diabetes Is a Risk Factor for Suffering and for in-Hospital Mortality with Pulmonary Embolism. A Population-Based Study in Spain (2016-2018).

Authors:  Rodrigo Jiménez-García; Romana Albaladejo-Vicente; Valentin Hernandez-Barrera; Rosa Villanueva-Orbaiz; David Carabantes-Alarcon; Javier de-Miguel-Diez; José Javier Zamorano-Leon; Ana Lopez-de-Andres
Journal:  Int J Environ Res Public Health       Date:  2020-11-11       Impact factor: 3.390

6.  Prevalence and sex- and age-related risk of pulmonary embolism in in-hospital patients with atrial fibrillation: a multicenter retrospective study from China.

Authors:  Ying Bai; Qiao-Min Yue; He Sun; Shi-Dong Guo; Zhen-Zhou Wang; Peng Zhong; Xue-Yao Wei; Lin Sun; Yue Liu; Xu-Bo Shi; Yan-Ting Liu
Journal:  Ann Transl Med       Date:  2020-12

Review 7.  Anticoagulation for atrial fibrillation in active cancer.

Authors:  Dimitrios Farmakis; Pavlos Papakotoulas; Eleni Angelopoulou; Theodoros Bischiniotis; George Giannakoulas; Panagiotis Kliridis; Dimitrios Richter; Ioannis Paraskevaidis
Journal:  Oncol Lett       Date:  2022-02-17       Impact factor: 2.967

8.  Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism.

Authors:  Behnood Bikdeli; David Jiménez; Jorge Del Toro; Gregory Piazza; Agustina Rivas; José Luis Fernández-Reyes; Ángel Sampériz; Remedios Otero; José María Suriñach; Carmine Siniscalchi; Javier Miguel Martín-Guerra; Joaquín Castro; Alfonso Muriel; Gregory Y H Lip; Samuel Z Goldhaber; Manuel Monreal
Journal:  J Am Heart Assoc       Date:  2021-08-28       Impact factor: 5.501

9.  Association between serum albumin levels and paroxysmal atrial fibrillation by gender in a Chinese population: a case-control study.

Authors:  Xia Zhong; Huachen Jiao; Dongsheng Zhao; Jing Teng
Journal:  BMC Cardiovasc Disord       Date:  2022-08-28       Impact factor: 2.174

10.  Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial fibrillation patients.

Authors:  Pamela L Lutsey; Faye L Norby; Neil A Zakai; Richard F MacLehose; Lin Y Chen; Surbhi Shah; Yvonne H Datta; Alvaro Alonso
Journal:  Curr Med Res Opin       Date:  2018-12-03       Impact factor: 2.580

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.